ebook img

Molecular Medicine Today 1996: Vol 2 Index PDF

25 Pages·1996·5.1 MB·English
by  
Save to my drive
Quick download
Download
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.

Preview Molecular Medicine Today 1996: Vol 2 Index

Author Index Subject Index Books and Electronic Resources Reviewed 1996 Vol 2 Issues 1—12 ISSN 1357 4329 Molecular Medicine Today Elsevier Trends Journals 68 Hills Road Cambridge UK CB2 1LA Tel: +44 1223 315961 Fax: +44 1223 464430 +44 1223 321410 e-mail: mmt.trends @elsevier.co.uk Advisory Editorial Board S. Agrawal, Worcester, USA P. Berg, Stanford, USA H. Blau, Stanford, USA T. Blundell, Cambridge, UK D. Choi, St Louis, USA T. Cox, Cambridge, UK K. Culver, Gaithersburg, USA K. Davies, Oxford, UK I. Dunham, Hinxton, UK R. Flavell, New Haven, USA D. Gordon, London, UK W. Giinzburg, Vienna, Austria J.M. Leiden, Chicago, USA M.A. Liu, West Point, USA K. Matsushima, Kanasawa, Japan A. McMichael, Oxford, UK M. Noble, Salt Lake City, USA W. Petri, Charlottesville, USA B. Ponder, Cambridge, UK D. Prockop, Philadelphia, USA Z. Ram, Tel-Hashomer, Israel T. Soussi, Paris, France L-C. Tsui, Toronto, Canada D. Young, London, UK H. zur Hausen, Heidelberg, Germany Editor Rebecca Jones Assistant Editor Catherine Brooksbank Editorial Administrator Sandra Taylor Publisher Peter Desmond © 1997 Elsevier Science Ltd. All rights reserved. This journal and the individual contributions contained in it are protected by the copyright of Elsevier Science Ltd. Except as outlined in the terms and conditions, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher, Elsevier Trends Journals, 68 Hills Road, Cambridge, UK CB2 1LA. AUTHOR INDEX Abbreviations: (B), The books; (C), The letters; (L), The literature; (M), The meetings; (N), News; (O), Opinion; (P), Perspectives; (W), The web A Castleberry, R.P., see Emanuel, P.D. Dewhurst, S., Sander, D.M. and Sgro, Abbott, N.J. and Romero, [.A., Chanda, S. and Mehendale, H.M., J-Y., Resources for HIV/AIDS on the Transporting therapeutics across the Hepatic cell division and tissue Internet (W) 52 blood-brain barrier 106 repair: a key to survival after liver Diamond, B., see Malkiel, S. Alberti, S., Development of ulcerative injury 82 Dougherty, G.J., see Klingemann, H-G. colitis: evidence from animal models Chauhan, A.J., Krishna, M.T. and (O) 272 Holgate, S.T., Aetiology of asthma: E Altman, J., A biological view of drug how public health and molecular Ellis, J., Retroviral gene therapy: as easy abuse (P) 237 medicine work together (P) 192 asa,B,y?(L) 319 Anderson, K.C., see Vidriales, M.B. Clarke, A.R., Sphyris, N. and Harrison, Emanuel, P.D., Shannon, K.M. and D.J., Apoptosis in vivo and in vitro: Castleberry, R.P., Juvenile B conflict or complementarity? (O) myelomonocytic leukemia: molecular Bachinski, L.L. and Roberts, R., Familial 189 understanding and prospects for hypertrophic cardiomyopathy: Clayton Smith, J., see Read, A.P. therapy 468 diagnostic and therapeutic implications Coffey, A., Towards gene therapy for Evans, K.L., Genetics of mental of recent genetic studies 387 Duchenne muscular dystrophy (L) 8 retardation and manic depression Baker, D.A., Receptors for malaria Cohen, J.J., Sellins, K.S. and Lamb, (L) 362 adhesion (L) 277 C.A., Death and the immune response Evans, K.L., Minibrain genes and critical Bevan, S., The interferon yy response: an (B) 230 loci for Down syndrome (L) 495 eternally branching pathway? (L) 9 Culver, K.W., Gene therapy (poster) Evans, K.L., Polycystic kidney disease Blackwell, C.C., Infectious agents and Culver, K.W., Measuring success in and triplet repeats (L) 186 sudden infant death syndrome clinical gene therapy research (O) (SIDS): an update (C) 94 234 F Blackwell, J.M., Structure and function Fayers, P.M., Randomization in clinical of the natural-resistance-associated D trials and experimental molecular macrophage protein (Nramp1), a Daiger, S.P., see Sullivan, L.S. research (O) 366 candidate protein for infectious and Danilenko, D.M., Ring, B.D. and Pierce, Featherstone, C., Fish tales (N) 92 autoimmune disease susceptibility G.F., Growth factors and cytokines Featherstone, C., HLA-derived peptides 205 in hair follicle development and in clinical trial for kidney allografts Booy, R., see Kroll, J.S. cycling: recent insights from animal (N) 447 Borst, P., Books on cancer (B) 370 models and the potentials for clinical Featherstone, C., Intracellular Botting, J., The Frankenstein syndrome therapy 460 immunization or immunotherapy for (B) 58 Danos, O., see Naffakh, N. HIV infection? (N) 271 Brilliant, M.H., see Oetting, W.S. Davenport, M.P. and Hill, A.V.S., Featherstone, C., MHC-binding peptide Brinkmann, U., Recombinant Reverse immunogenetics: from prediction on the Web(N) 491 immunotoxins: protein engineering HLA-disease associations to vaccine Featherstone, C., RB gene therapy for for cancer therapy 439 candidates 38 bladder cancer (N) 182 Brooksbank, R.A., Kidney stones: three Davies, D.H., Immunology reference Featherstone, C., Vaccines by agriculture disorders from a single gene (L) 146 books (B) 143 (P) 278 Buckle, A-M., Stem cells down to a T De Grandis, D., see Montecucco, C. Fine, S.M., see Dewhurst, S. (L) 97 de Villiers, W.J.S., From the gut to the Fischman, A.J., see Hamberg, L.M. Bult, H., Nitric oxide and atherosclerosis: brain (L) 363 Fricker, J., Blood stem cells to the rescue possible implications for therapy 510 de Villiers, W.J.S., Gene de(liver)y to in ovarian cancer(N) 181 Bustin, S.A., Circulating tyrosinase- the wall(L) 186 Fricker, J., Canarypox as a vector for positive cells in melanoma (L) 362 de Villiers, W.J.S., Genes, cytokines and HIV vaccine (N) 225 the gut(L) 277 Fricker, J., Fanconi’s anaemia, cord C de Villiers, W.J.S., On the importance of blood transplant and gene therapy Caruso, M., Gene therapy against cancer the appendix (L) 450 (N) 406 and HIV infection using the gene Dewhurst, S., Gelbard, H.A. and Fine, Fricker, J., Hepatitis E vaccine (N) 137 encoding herpes simplex virus S.M., Neuropathogenesis of AIDS Fricker, J., Hepatocellular carcinoma and thymidine kinase 212 16 p53 gene therapy (N) 361 Fricker, J., Interleukin 7 on trial for Harby, K., Using fetus-derived tissues Klingemann, H-G. and Dougherty, G.J., melanoma treatment (N) 2 for molecular medicine: tension Site-specific delivery of cytokines in Fricker, J., Naked DNA for malaria between research and ethics (P) 326 cancer 154 vaccines (N) 91 Harrington, C.R., Dementia with Lewy Krishna, M.T., see Chauhan, A.J. bodies: the continuing enigma (M) 4 Kroll, J.S. and Booy, R., Haemophilus G Harrison, D.J., see Clarke, A.R. influenzae: capsule vaccine and Gahring, L.C., see Rogers, S.W. Hatmi, M., New phospholipases and capsulation genetics 160 Gazzinelli, R.T., Molecular and cellular cyclooxygenases as novel drug targets Kuan, A.P., see Malkiel, S. basis of interleukin 12 activity in (M) 496 prophylaxis and therapy against Heath, A., CD40-independent antibody- L infectious diseases 258 isotype switching (L) 408 Lamb, C.A., see Cohen, J.J. Gelbard, H.A., see Dewhurst, S. Heath, A., Mosquitoes, indigestion and Leiden, J.M., see Svensson, E.C. Glaser, V., Gene transfer to the liver malaria (L) 233 Lindsay, J.A., Infectious agents and (N) 47 Henz, B.M., see Schadendorf, D. sudden infant death syndrome Glaser, V., RNase L and 2-5A to Hewitt, C.R.A., Alveolar macrophages (SIDS): an update (C) 94 enhance antisense technology and just say NO(L) 51 Liiilmann, H., Homeopathy: science or target the destruction of MRNA Hewitt, C.R.A., Breaking down scam? revisited (C) 59 (N) 183 immunity to the fungal wall (L) 495 Lyng, H., see Rofstad, E.K. Gore, M., New methodology for the Hewitt, C.R.A., C3d complements evaluation of novel therapies in immunity (L) 96 M cancer (P) 103 Hill, A.V.S., see Davenport, M.P. Mahendra, P., GSTT/ gene defect may Greaves, D.R., A C-x—C chemokine Hill, C.M., Can you resist HIV-1 increase risk of myelodysplasia (L) mobilizes haemopoietic precursor infection? (L) 494 186 cells(L) 232 Hoehner, J.C., see Pahlman, S. Mahendra, P., Sickle cell disease: a Greaves, D.R., HHV-6 increases Holgate, S.T., see Chauhan, A.J. continuing clinical and research haemopoietic progenitor cell Holt, J., Antisense therapeutics (M) 184 dilemma (L) 450 susceptibility to HIV (L) 409 Holzman, D., Gene therapy for HER-2- Mahendra, P., Survival with autologous Greaves, D.R., On the role of COX-2 in related cancer(N) 138 BMT compared with intensive rheumatoid arthritis (L) 363 Holzman, D., Testosterone, wasting and chemotherapy (L) 319 Greaves, D.R., On the role of the L in AIDS (N) 93 Malkiel, S., Kuan, A.P. and Diamond, LPS (L) 187 Holzman, D.C., Cytomegalovirus and B., Autoimmunity in heart disease: Greaves, D.R., see Nolan, K. restenosis (N) 270 mechanisms and genetic Greaves, D.R., Shocking developments Holzman, D.C., Interferon a, GM2 susceptibility 336 in transdermal drug delivery (L) 9 antigen and melanoma Man, S., (CTL) Memories of Jenner (L) Greaves, D.R., Two’s company, three immunotherapy (N) 359 276 allows for post-translational Humphries, M.J., see Newham, P. Man, S., Eve of distraction for CTL (L) modification (L) 50 Hunter, G.J., see Hamberg, L.M. 50 Man, S., p53 peptides for cancer H J vaccines (L) 147 Hamberg, L.M., Hunter, G.J. and Jack, D., Bee-glue reveals anti- Man, S., see Skipper, J. Fischman, A.J., Use of positron inflammatory properties plus... (N) Mandell, G.L., see Sable, C.A. emission tomography to study tumors 271 Martin, R., Tissue regeneration enhanced in vivo 528 Jack, D.B., Drug-resistant bacteria: by PDGF-A (L) 97 Harada, A., Mukaida, N. and responding to the infectious disease Martin, R., Turning muscles into Matsushima, K., Interleukin 8 as a crisis (P) 499 cartilage and bone (L) 146 novel target for intervention therapy Jack, D.B., Herpes simplex virus and Matsushima, K., see Harada, A. in acute inflammatory diseases Alzheimer’s disease (N) 270 McCabe, D., see Yang, N-S. 482 Jack, D.B., Spider farming, spider McCormick, F., see Kirn, D.H. Harby, K., Attention deficit continues to venom and neurexins (N) 1 McKay, I.A., Engineered antibodies to attract research attention (N) 493 Jack, D.B., Traditional chinese medicine fight melanoma (L) 451 Harby, K., Genes on a chip for tissue yields a kinase inhibitor for use in McKay, I.A., Topical macrolides: expression and HIV study (N) 317 cancer and HIV (N)_ 137 fixing skin from the outside in (L) Harby, K., Major US funding for Jordan, V.C., see Tonetti, D.A. 2352 engineered biomaterials (N) 360 McKenzie, K., see Sukumar, S. Harby, K., Menopause: disease state or K Mehendale, H.M., see Chanda, S. state of nature? Implications for Kampe, O., see Winqvist, O. Montecucco, C., Schiavo, G., Tugnoli, molecular medicine (P) 414 Kaufmann, S.H., Proteolytic cleavage V. and De Grandis, D., Botulinum Harby, K., MR microscopy: a new during chemotherapy-induced neurotoxins: mechanism of action and window to the lungs (N) 139 apoptosis 298 therapeutic applications 418 Harby, K., Muscle to power artificial Kilbourn, R.G., Nitric oxide: moving Moskowitz, D.W., Genetic screening and heart (N) 49 towards the clinic (M) 324 diagnosis of disease (M) 275 Harby, K., Tissue-engineered cartilage King, R.A., see Oetting, W.S. Mousa, S.A., Angiogenesis promoters attracts research interest (N) 492 Kirn, D.H. and McCormick, F., and inhibitors: potential therapeutic Harby, K., Umbilical cord blood: waste Replicating viruses as selective applications (M) 140 not, want not(N) 182 cancer therapeutics 519 Mukaida, N., see Harada, A. N Popoff, S.N. and Schneider, G.B., Schneider, M.C., Advances in polycystic Naffakh, N. and Danos, O., Gene transfer Animal models of osteopetrosis: the kidney disease 70 for erythropoiesis enhancement 343 impact of recent molecular Segal, A.W., The NADPH oxidase and Neil, J.C., Books on HIV (B) 412 developments on novel strategies for chronic granulomatous disease 129 Newham, P. and Humphries, M.J., therapeutic intervention 349 Sellins, K.S., see Cohen, J.J. Integrin adhesion receptors: structure, Senechal, K. and Sawyers, C.L., Signal function and implications for R transduction-based strategies for the biomedicine 304 Radich, J., Gene quantification now (M) treatment of chronic myelogenous Nolan, K. and Greaves, D.R., IL-12 228 leukemia 503 anticancer gene therapy: magic Raju, R., Ontogeny of GAD, an Senior, K., Homeopathy: science or bullets from a golden gun (L) autoantigen in diabetes (L) 318 scam? revisited (C) 59 451 Ramsay, M., SOX9 and male sex Senior, K., Acupuncture: can it take the Novelli, G., Spinal muscular atrophy: determination (L) 494 pain away? (P) 150 resources available on the World Raynes, J., Regulation of interleukin 12 Senior, K., Pharmaceuticals from plants: Wide Web (C) 369 induction by the Rel family (L) 8 promise and progress (P) 60 Read, A.P. and Clayton Smith, J., Sgro, J-Y., see Dewhurst, S. O Databases for medical genetics (B) 7 Shannon, K.M., see Emanuel, P.D. O’Brien, C., Brain banks: treasures in Ring, B.D., see Danilenko, D.M. Sheppard, D.N. and Ostedgaard, L.S., store for molecular analysis (N) Roberts, R., see Bachinski, L.L. Understanding how cystic fibrosis 226 Rockett, K.. Handbook of methods in mutations cause a loss of C1- channel O’Brien, C., Differences that show up in nitric oxide research (B) 498 function 290 translation (N) 49 Rofstad, E.K. and Lyng, H., Xenograft Singer, R.H., Triplet repeats and human O’Brien, C., Embryo project in gestation model systems for human melanoma disease 65 onthe Net(N) 405 394 Skipper, J. and Man, S., Immunology O’Brien, C., Encapsulated xenogeneic Rogers, S.W., Twyman, R.E. and resources on the World Wide Web cells: delivering CNTF to motor Gahring, L.C., The role of (W) 320 neurons (N) 448 autoimmunity to glutamate receptors Skuse, D., Genes and behavioural O’Brien, C., Hyperthermia: getting in neurological disease 76 phenotypes (B) 325 tumours to feel the heat (N) 48 Rollins, B.J., Monocyte chemoattractant Snider, B.J., Genetics of epilepsy (L) 318 O’Brien, C., Post-Lyme-disease protein 1: a potential regulator of Snider, B.J., Processing progress in syndrome under trial (N) 407 monocyte recruitment in Alzheimer’s disease (L) 409 O’Brien, C., Protein fingerprints, inflammatory disease 198 Soderbergh, A., see Winqvist, O. proteome projects and implications Romero, I.A., see Abbott, N.J. Soussi, T., The p53 tumor suppressor for drug discovery (N) 316 Rook, G.A.W.., Stress proteins in gene: a model for molecular O’Brien, C., TNF receptor fusion protein medicine (B) 188 epidemiology of human cancer 32 in rheumatoid arthritis (N) 269 Rosser, A., Medical textbooks (B) 413 Sphyris, N., see Clarke, A.R. O’Brien, C., Type | diabetes gets the Rowe, P.M., Xenotransplantation: from Springer, M.L., Towards a treatment for genomics treatment (N) 360 animal facility to the clinic? (P) 10 Tay-Sachs disease (L) 232 Oetting, W.S., Brilliant, M.H. and King, Stagg, A.J., A second HLA-B27 R.A., The clinical spectrum of S transgene model of human albinism inhumans 330 Sable, C.A. and Mandell, G.L., The role spondylarthropathy (L) 51 Ostedgaard, L.S., see Sheppard, D.N. of molecular techniques in the Stagg, A.J., Bacterial DNA as a potent understanding of emerging infections immunostimulant (L) 233 ls 120 Steel, C.M., Books on cancer (B) 370 Pahlman, S. and Hoehner, J.C., Sale, G.E., Does graft-versus-host Stewart, A., Chromosomes in colour Neurotrophin receptors, tumor disease attack epithelial stem cells? (N) 492 progression and tumor maturation 114 Sukumar, S. and McKenzie, K., Breast 432 Sander, D.M., see Dewhurst, S. cancer prevention strategies for the Palmer, M.S., Free radical production Sander, T., The genetics of idiopathic twenty-first century (P) 453 implicated in ALS (L) 408 generalized epilepsy: implications for Sullivan, L.S. and Daiger, S.P., Inherited Palmer, M.S., Liposomes for gene the understanding of its aetiology retinal degeneration: exceptional therapy (L) 147 173 genetic and clinical heterogeneity Paterson, M., Sequence databases and Sawyers, C.L., see Senechal, K. 380 homology searching using the World Schadendorf, D., Henz, B.M. and Wittig, Sun, W.H., see Yang, N-S. Wide Web (W) 98 B., Interleukin 7 trials for melanoma Svensson, E.C., Tripathy, S.K. and Patrizio, P. and Zielenski, J., Congenital treatment (C) 144 Leiden, J.M., Muscle-based gene absence of the vas deferens: a mild Scherer, S.W., Alanine stretches in HOX therapy: realistic possibilities for the form of cystic fibrosis 24 proteins, limb development and future 166 Pi-Sunyer, F.X., Obesity: advances in evolution (L) 276 understanding and treatment (M) Scherer, S.W., Duplication of DNA and T 410 disease (L) 187 Tebbutt, S.J., Cystic fibrosis resources on Pierce, G.F., see Danilenko, D.M. Scherer, S.W., The Human Genome the World Wide Web (W) 148 Plenat, F., Animal models of antisense Project: another step closer (L) 96 Tonetti, D.A. and Jordan, V.C., Targeted oligonucleotides: lessons for use in Schiavo, G., see Montecucco, C. anti-estrogens to treat and prevent humans 250 Schneider, G.B., see Popoff, S.N. diseases in women 218 Torchilin, V.P., Liposomes as delivery Vickers, A., Homeopathy: science or Wittig, B., see Schadendorf, D. agents for medical imaging 242 scam? revisited (C) 59 Tripathy, S.K., see Svensson, E.C. Vidriales, M.B. and Anderson, K.C., X Tugnoli, V., see Montecucco, C. Adhesion of multiple myeloma cells Xu, Q. and Wick, G., The role of heat Twyman, R.E., see Rogers, S.W. to the bone marrow shock proteins in protection and microenvironment: implications for pathophysiology of the arterial wall Vv future therapeutic strategies 425 372 Vainio, H., Books on cancer (B) 370 Veggeberg, S., High-performance Ww Y antioxidants for a multitude of Walker, C.L., Cancer susceptibility Yang, N-S., Sun, W.H. and McCabe, D., diseases (N) 406 genes and molecular carcinogenesis Developing particle-mediated Veggeberg, S., Online health and healing (M) 364 gene-transfer technology for (N) 315 Wick, G., see Xu, Q. research into gene therapy of cancer Veggeberg, S., Researchers to throw Wilkie, A., Books on molecular genetics 476 antisense against brain tumors (N) (B) 452 48 Wingqvist, O., Séderbergh, A. and Z Veggeberg, S., US studies fail to find Kéampe, O., The autoimmune basis of Zielanski, J., see Patrizio, P. link between Gulf War and birth adrenocortical destruction in defects (N) 3 Addison’s disease 282 SUBJECT INDEX Compiled by Carol Featherstone Abbreviations: (B), The books; (C), The letters; (L), The literature; (M), The meetings; (N), News; (O), Opinion; (P), Perspectives; (W), The web A premature ovarian failure 282 hair follicle development and cycling 2-5A-antisense chimeras (N) 183 steroid hormone synthesis 282 460 respiratory syncytial virus (RSV) adenovirus mouse models 460 (N) 183 oncolytic activity 519 therapeutics delivery 460 RNA-dependent protein kinase (N) adenovirus vectors therapies 460 183 erythropoietin gene transfer 343 alveolar macrophages RNase L(N) 183 liver gene therapy (L) 186 lymphocytostatic activity (L) 51 absence epilepsy 173 muscle-based gene therapy 166 nitric oxide (NO) (L) 51 acetaminophen (paracetamol) adhesion Alzheimer’s disease (M) 4 hepatotoxicity 82 integrins 304 B-amyloid precursor protein acetylcholine release adhesion molecules processing (L) 409 botulinum neurotoxins 418 multiple myeloma 425 apolipoprotein E4 allele (N) 270 acupuncture (P) adrenal gland destruction herpes simplex virus type 1 (N) 270 anaesthesia (P) 150 Addison’s disease 282 neuropathological diagnosis (M) 4 history (P) 150 f-adrenoceptor agonists neurotrophins 432 meridians (P) 150 obesity (M) 410 presenilin | and2(L) 409 meta-analysis of clinical trials (P) aflatoxin B1 secreted B-amyloid precursor protein 150 hepatocellular carcinoma 32 (L) 409 neurochemical basis (P) 150 p53 tumour suppressor gene mutation amylin observed effects (P) 150 32 obesity (M) 410 pain relief (P) 150 AIDS see also HIV infection appetite suppressants (M) 410 points (P) 150 apoptosi(sO ) 189 B-amyloid precursor protein safety (P) 150 cachexia(N) 93 Alzheimer’s disease (L) 409 acute myeloid leukemia CCRS null mutant allele (L) 494 presenilin 1 and2(L) 409 intensive chemotherapy (L) 319 dementia 16 processing (L,.) 409 autologous bone marrow Internet resource(sW ) 52 secretion (L) 409 transplantation (L) 319 plant-derived medicines (P) 60 amyotrophic lateral sclerosis (ALS) acute vascular rejection progressio(nL ) 494 CNTF delivery technology (N) 448 xenotransplantation (P) 10 resources (W) 52 copper-—zinc superoxide dismutase | acute viral hepatitis testosteron(eN ) 93 gene mutations (L) 408 hepatitis E virus vaccine (N) 137 wasting (N) 93 free radicals (L) 408 acyclovir airway inflammation neurotrophins (N) 432, 448 cancer 212 asthma (P) 192 anaemia gene therapy 212 albinism erythropoietin treatment 343 herpes simplex virus thymidine eye development 330 gene therapy 343 kinase gene (HSV tk) 212 Hermansky—Pudlak syndrome 330 sickle cell anaemia 343 HIV infection 212 loci 330 B-thalassaemia 343 addictive drugs (P) 237 melanin synthesis 330 anaesthesia actions (P) 237 oculocutaneous albinism 330 acupuncture (P) 150 dopamine (P) 237 Pgene 330 anatomy atlases pharmacotherapeutic agents (P) tyrosinase 330 magnetic resonance microscopy (N) substitute drugs (P) 237 X-linked ocular albinism 330 139, 405 Addison’s disease alcoholism anemia see anaemia adrenal gland destruction 282 genetic contribution (P) 237 anesthesia see anaesthesia autoantibodies 282 allograft survival angiogenesis autoantigen epitopes 282 HLA-derived peptides (N) 447 angiostatic molecules (M) 140 autoimmune polyendocrine syndrome alopecia anticancer therapies (M) 140 282 cancer therapies 460 cell adhesion molecules (M) 140 autoimmune responses 282 cytokines 460 cytokines (M) 140 cellular autoimmunity 282 growth factors and their receptors growth factors (M) 140 immunogenetics 282 460 integrin a,B,(M) 140 laminin(M) 140 2—5A-—antisense chimeras (N) 183 heat shock proteins 372 matrix (M) 140 oligonucleotide stability 250 arthritis metastasis (M) 140 respiratory syncytial virus (RSV) (N) cyclooxygenase-2 inhibitor (L) 363 regulators (M) 140 183 interleukin 6(L) 363 sulphated oligosaccharides (M) 140 RNA-dependent protein kinase (N) spontaneous inflammatory (L) 51 therapeutics (M) 140 183 transgenic mouse model (L) 51 vascular endothelial growth factor RNase L(N) 183 artificial organs (VEGF) (M) 140 antisense gene therapy development (N) 360 angiostatic molecules (M) 140 glioma (N) 48 heart (N) 49 antibiotic-resistant bacteria (P) 499 transforming growth factor B, assisted reproduction antibiotic misuse (P) 499 (TGF-B,)(N) 48 congenital absence of the vas extended-spectrum B-lactamases (P) viral vectors (M) 184 deferens (CAVD) 24 499 antisense therapeutics asthma mechanisms (P) 499 animal studies 250 aetiology (P) 192 multidrug resistant bacteria (P) 499 cellular uptake 250 airway inflammation (P) 192 new drugs (P) 499 chronic myelogenous leukaemia atopy (P) 192 phenothiazines (P) 499 (CML) 503 clinical management (P) 192 prevention (P) 499 cytomegalovirus-induced retinitis cytokines (P) 192 resistance genes in antibiotics (P) (M) 184 drugs (P) 192 499 oligonucleotide analogues 250 environmental factors (P) 192 tuberculosis re-emergence (P) 499 oral oligonucleotide administration foetal programming (P) 192 antibody isotype switching (L) 408 (M) 184 genetic factors (P) 192 anticancer drugs large-scale oligonucleotide synthesis house dust mite (P) 192 plant-derived (P) 60 (M) 184 inhaled allergens (P) 192 anticancer therapies respiratory syncytial virus (RSV) nitric oxide (NO) (P) 192 angiogenesis inhibitors (M) 140 infection (M) 184 public health policy (P) 192 anti-estrogens see anti-oestrogens route of administration 250 tissue remodelling (P) 192 anti-integrin therapies 304 pharmacokinetics 250 treatment guidelines (P) 192 anti-oestrogens specificity 250 atherogenesis bone density 218 toxicity studies (M) 184, 250 endothelial cell nitric oxide synthase breast cancer 218 antiviral activity (eNOS) 510 endocrine therapy 218 interferon y(L) 9 endothelium-dependent vasodilation endometrial carcinoma 218 transcription factors (L) 9 510 hepatocellular carcinoma 218 antiviral therapy hypercholesterolaemia 510 hormone replacement therapy 218 translation-targete(dN ) 49 inducible nitric oxide synthase myocardial infarction 218 apical Cl channel function (iNOS) 510 oestrogen receptor 218 cystic fibrosis 290 monocyte adhesion 510 osteoporosis 218 apolipoprotein E4 allele monocyte chemoattractant protein 1 prevention of breast cancer Alzheimer’s disease (N) 270 (MCP-1) 198 tamoxifen 218 apoptosis nitric oxide (NO) 510 target-site specificity 218 AIDS (O) 189 oxidant stress 510 antifungal drug screen(N) 49 basal-cell carcinoma (O) 189 superoxide anion 510 antigenic peptides 38 books (B) 230 atherosclerosis database (N) 491 cancer (O) 189, 364 autoimmunity 372 HIV (N) 491 CD4* T cells (O) 189 cell-mediated immune responses prediction(N) 491 chemotherapy-induced 298 372 sequencing 38 ICE-related proteases 298 endothelial cell nitric oxide synthase tolerogens 38 immune cells (B) 230 (eNOS) 510 vaccines 38, (N) 491 interleukin-18 converting enzyme endothelium-dependent vasodilation anti-inflammatory (ICE) 298 510 non-steroidal anti-inflammatory drugs in vivo studies (O) 189 heat shock proteins (HSP) 372 (NSAIDs) (M) 496 neoplasia (O) 189 hypercholesterolaemia 510 propolis (N) 271 p53(O) 189 inducible nitric oxide synthase antimalarial drugs pathology (O) 189 (iNOS) 510 artemisin (P) 60 proteases 298 monocyte adhesion 510 antimicrobial immunity proteolysis substrates 298 nitric oxide (NO) 510 natural-resistance-associated appendix oxidant stress 510 macrophage protein (NRAMP1) inflammatory bowel disease (L) 450 superoxide anion 510 205 mucosal immune system (L) 450 therapies 510 antioxidants T cell receptor a knockout mice (L) atopy synthetic (N) 406 450 asthma (P) 192 antiprotozoal drugs appetite suppressants (M) 410 attention-deficient hyperactivity disorder plant-derived (P) 60 artemisin (ADHD) propolis (N) 271 malaria (P) 60 behaviour-modifying drugs (N) 493 antisense-enhancing technology arterial wall homeostasis genetic involvement (N) 493

See more

The list of books you might like

Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.